Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis.
Advanced sarcoidosis
Diffusion capacity
Mortality
PF-ILD
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
25 Jun 2022
25 Jun 2022
Historique:
received:
12
12
2021
accepted:
21
05
2022
entrez:
25
6
2022
pubmed:
26
6
2022
medline:
29
6
2022
Statut:
epublish
Résumé
Advanced pulmonary sarcoidosis causes significant morbidity and can lead to death. Large trials demonstrated efficacy of antifibrotics in patients with progressive fibrosing interstitial lung diseases (PF-ILD), including a few with sarcoidosis. To date, little is known about this progressive fibrosing phenotype in sarcoidosis. Diffusion capacity of carbon monoxide (DLCO) may be a useful functional marker to screen for advanced pulmonary sarcoidosis. In this study, we describe a cohort with advanced pulmonary sarcoidosis and we gain insights in the progressive fibrosing phenotype in sarcoidosis. Patients with sarcoidosis and a DLCO < 50% predicted were included in this retrospective cohort study. First measurement of DLCO < 50% predicted was the baseline. Lung function data, HRCT, pulmonary hypertension (PH) and mortality were collected. Patients with > 10% fibrosis on HRCT meeting the criteria for ILD-progression within 24 months were labelled as PF-ILD. With Cox-regression analysis predictors of mortality were established. 106 patients with a DLCO < 50% predicted were included. Evolution of forced vital capacity (FVC) varied widely between patients from - 34% to + 45% after 2 years follow-up, whereas change in DLCO varied between - 11% and + 26%. Fourteen patients (15%) met the PF-ILD criteria, of whom 6 (43%) died within 10 years versus 10 (13%) in the non PF-ILD group (p = 0.006). PH was present 12 (11%), 56 (53%) demonstrated > 10% fibrosis on HRCT. Independent predictors of mortality and lung transplantation in the whole cohort are PH, PF-ILD and UIP-like pattern. In conclusion, within this group with advanced pulmonary sarcoidosis disease course varied widely from great functional improvement to death. PF-ILD patients had higher mortality rate than the mortality in the overall pulmonary sarcoidosis group. Future research should focus on the addition of antifibrotics in these patients. Trial registration retrospectively registered.
Sections du résumé
BACKGROUND
BACKGROUND
Advanced pulmonary sarcoidosis causes significant morbidity and can lead to death. Large trials demonstrated efficacy of antifibrotics in patients with progressive fibrosing interstitial lung diseases (PF-ILD), including a few with sarcoidosis. To date, little is known about this progressive fibrosing phenotype in sarcoidosis. Diffusion capacity of carbon monoxide (DLCO) may be a useful functional marker to screen for advanced pulmonary sarcoidosis. In this study, we describe a cohort with advanced pulmonary sarcoidosis and we gain insights in the progressive fibrosing phenotype in sarcoidosis.
METHODS
METHODS
Patients with sarcoidosis and a DLCO < 50% predicted were included in this retrospective cohort study. First measurement of DLCO < 50% predicted was the baseline. Lung function data, HRCT, pulmonary hypertension (PH) and mortality were collected. Patients with > 10% fibrosis on HRCT meeting the criteria for ILD-progression within 24 months were labelled as PF-ILD. With Cox-regression analysis predictors of mortality were established.
RESULTS
RESULTS
106 patients with a DLCO < 50% predicted were included. Evolution of forced vital capacity (FVC) varied widely between patients from - 34% to + 45% after 2 years follow-up, whereas change in DLCO varied between - 11% and + 26%. Fourteen patients (15%) met the PF-ILD criteria, of whom 6 (43%) died within 10 years versus 10 (13%) in the non PF-ILD group (p = 0.006). PH was present 12 (11%), 56 (53%) demonstrated > 10% fibrosis on HRCT. Independent predictors of mortality and lung transplantation in the whole cohort are PH, PF-ILD and UIP-like pattern.
CONCLUSION
CONCLUSIONS
In conclusion, within this group with advanced pulmonary sarcoidosis disease course varied widely from great functional improvement to death. PF-ILD patients had higher mortality rate than the mortality in the overall pulmonary sarcoidosis group. Future research should focus on the addition of antifibrotics in these patients. Trial registration retrospectively registered.
Identifiants
pubmed: 35752806
doi: 10.1186/s12931-022-02094-7
pii: 10.1186/s12931-022-02094-7
pmc: PMC9233403
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
169Subventions
Organisme : ZonMw
ID : 842002001
Pays : Netherlands
Informations de copyright
© 2022. The Author(s).
Références
Eur Respir J. 2020 Aug 13;56(2):
pubmed: 32381492
Respirology. 2016 May;21(4):712-7
pubmed: 26699835
Am J Respir Crit Care Med. 2011 Jun 1;183(11):1524-30
pubmed: 21330454
Chest. 2006 May;129(5):1246-52
pubmed: 16685015
Respir Med. 2020 Aug;169:105997
pubmed: 32442108
Chest. 2018 Jan;153(1):105-113
pubmed: 28728933
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Am J Med. 1986 May;80(5):807-12
pubmed: 3706368
Clin Immunol. 2019 Feb;199:57-61
pubmed: 30543925
Respir Med. 2019 Oct;157:69-76
pubmed: 31522032
Clin Respir J. 2009 Oct;3(4):207-13
pubmed: 20298406
Eur Respir J. 2008 Aug;32(2):296-302
pubmed: 18385166
AJR Am J Roentgenol. 2000 Jun;174(6):1751-7
pubmed: 10845518
Lancet Respir Med. 2014 Feb;2(2):123-30
pubmed: 24503267
N Engl J Med. 2014 May 29;370(22):2083-92
pubmed: 24836312
N Engl J Med. 2015 Aug 20;373(8):782
pubmed: 26287867
Eur Respir J. 2011 Dec;38(6):1368-73
pubmed: 22075486
Ann Thorac Med. 2010 Apr;5(2):86-91
pubmed: 20582173
Eur Respir J. 2019 Oct 31;54(4):
pubmed: 31320453
Respiration. 2020;99(10):838-845
pubmed: 33264777
N Engl J Med. 2018 Dec 6;379(23):2209-2219
pubmed: 30345907
Eur Respir J. 2010 Dec;36(6):1315-22
pubmed: 20378598
ERJ Open Res. 2019 Oct 30;5(4):
pubmed: 31687368
Chest. 2005 Sep;128(3):1483-9
pubmed: 16162747
Sarcoidosis Vasc Diffuse Lung Dis. 1999 Sep;16(2):149-73
pubmed: 10560120
Am J Respir Crit Care Med. 2006 Sep 15;174(6):659-64
pubmed: 16778159
Thorax. 2016 Jan;71(1):45-51
pubmed: 26585524
Chest. 2015 Feb;147(2):438-449
pubmed: 25188873
Respir Med. 2018 Jun;139:72-78
pubmed: 29858005
BMC Pulm Med. 2019 Oct 31;19(1):192
pubmed: 31672127
Thorax. 2013 May;68(5):436-41
pubmed: 23321605
N Engl J Med. 2007 Nov 22;357(21):2153-65
pubmed: 18032765
Eur J Intern Med. 2020 Jul;77:59-65
pubmed: 32331839
BMC Pharmacol Toxicol. 2014 Nov 19;15:63
pubmed: 25410822
Am J Respir Crit Care Med. 2003 Apr 1;167(7):962-9
pubmed: 12663338
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307